RAB22A and osteosarcoma: Furthermore, via either knockdown or overexpression of Rab22a-NeoF1 in osteosarcoma cell lines and tumor tissues, they verified that Rab22a-NeoF1 could promote tumor migration and invasion, which might be a potential therapeutic target in patients with metastatic osteosarcoma.